Body Mass Index and Risk for COVID-19-Related Hospitalization in Adults Aged 50 and Older in Europe

Ohno, Maika; Dzúrová, Dagmar

doi:10.3390/nu14194001

Cited by 8 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, BMI, which has been felt to be a major risk factor both for SARS-CoV2 severity and transaminase elevation secondary to non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD) 20,21 , was not relevant, displaying no increased risk of transaminase elevation. However, as our hospital center serves a patient population with atypical demographics (see high percentage of Black race in demographics) this may be an outlier reflecting a specific resistance to NASH/NAFLD due to polymorphisms such as PNPLA-3 or MBOAT7 22 .…”

Section: Discussionmentioning

confidence: 99%

Older Age and Vaccination Protect Against Transaminase Elevation in Pediatric SARS-CoV2

Ovale,

Charles,

Rosenbaum

et al. 2024

Preprint

View full text Add to dashboard Cite

Objectives: SARS-CoV2 infection is reported to induce transaminase elevations. There are case reports of severe liver injury in adult SARS-CoV2 patients, and some have theorized that acute SARS-CoV2 infection may be a driver of severe liver injury in children. While pediatric hepatic injury has previously been described, clear shifts in immunogenic response secondary to prior immune exposure and vaccination since initial reports from 2020 warrant further evaluation. We sought to identify the impact of variant shifts and vaccination on this phenomenon in children. Methods: a retrospective cross sectional study of pediatric SARS-CoV2 patients seen at two hospital facilities in an urban neighborhood in New York City between March 2020 and March 2022 was conducted via chart review. Data was extracted relating to patients demographics, clinical presentation, including the level of care and the laboratory results of comprehensive metabolic panels (CMP). Results: 133 pediatric cases were identified as having SARS-CoV2 and CMP obtained in the same visit. Patients were predominantly Black (79.2%) and non-hispanic (87%) with a mean age of 9.2 years. Risk of transaminase elevation was increased in younger patients and patients with higher level of care. BMI was not a risk factor noted for transaminase elevation. Vaccination decreased degree, not incidence, of transaminase elevation but given low rates of vaccination unable to determine significance of protective efficacy. Conclusions: our study has identified a profound increased risk of transaminase elevation in younger patients, the absence of BMI as a correlating factor in our primarily black patient population, a shift towards non-specific AST elevation with variant windows, and a strong signal of vaccine protection.

show abstract

Section: Discussionmentioning

confidence: 99%

Older Age and Vaccination Protect Against Transaminase Elevation in Pediatric SARS-CoV2

Ovale,

Charles,

Rosenbaum

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Obesity and diabetes are risk factors for increasing the severity of COVID-19. 31,32 In T2DM patients, obesity is associated with poor early prognosis in COVID-19 patients. Albahrani et al 33 prove that obesity was identified as an independent risk factor for the risk of decreased oxygen saturation in COVID-19 patients.…”

Section: Discussionmentioning

confidence: 99%

The Impact of COVID-19 Severity on TNF-α and IFN-γ in T2DM Patients' PBMC Monocytes

Wahyurini,

Tahapary,

Wibowo

2024

J Indon Med Assoc

View full text Add to dashboard Cite

Introduction: Monocytes are very sensitive to changes in the metabolic environment, including hyperglycemia, such as type 2 diabetes mellitus (T2DM). T2DM is characterized by chronic low-grade inflammation and becomes one COVID-19 comorbid. TNF-α and IFN-γ are cytokines often linked to inflammation, the severity of COVID-19, and long COVID-19. This study aims to analyze the relationship between COVID-19 severity and TNF-α and IFN-γ in T2DM one month post-infection.Methods: This research is an experimental study at the Integrated Laboratory Faculty of Medicine, Universitas Indonesia, for four months. The total samples are 44 cryotubes of PBMC (18 T2DM and 26 Non-T2DM) from the CARAMEL study (COVID-19, Aging, and Cardiometabolic Risk Factors). PBMCs were stimulated with inactivated whole virions SARS-CoV-2 and incubated for 24 hours. Monocyte subsets and intracellular cytokines are detected by flow cytometry.Results: Research showed that IFN-γ in the T2DM group was higher in all subsets. There was no significant difference between the T2DM and non-T2DM groups. Based on the history of the severity of COVID-19, MedFI IFN-γ classic and intermediate monocytes differed significantly between the COVID-19 severity groups (p = 0.049 and p = 0.022). Further research is needed to analyze the risk factors involved.Conclusion: MedFI of classic and intermediate monocyte IFN-γ differed significantly between the severity of COVID-19. There were no significant differences between the T2DM and non-T2DM groups. The history of the severity of COVID-19 is significantly related to long COVID-19.

show abstract

“…According to a meta-analysis of 3700 individuals, 14.4% of patients hospitalized for severe SARS-CoV-2 symptoms acquired diabetes. The patients with "new diabetes" were more likely to need urgent treatment than those who already had diabetes before contracting the virus [153,154]. Even three years after the pandemic, researchers are still unsure whether COVID-19 speeds up the development of diabetes, causes it, or does both.…”

Section: Diabetes and Covid-19mentioning

confidence: 99%

Progress in Understanding Metabolic Syndrome and Knowledge of Its Complex Pathophysiology

et al. 2023

View full text Add to dashboard Cite

The metabolic syndrome (MetS), first introduced by Haller in 1975, was sometimes also known as insulin resistance syndrome, syndrome X, and plurimetabolic syndrome. In 1989, it was rechristened by Kaplan as the “Deadly Quartet” based on a consolidation of central obesity, impaired glucose tolerance, dyslipidemia, and systemic hypertension. MetS is positively associated with a pro-inflammatory and pro-thrombotic state, attributed to increased pro-thrombotic and inflammatory marker activity. Moreover, MetS is frequently associated with increased atherosclerotic cardiovascular disease, impaired glucose tolerance, hyperuricemia, obstructive sleep apnea, and chronic kidney disease. Despite concerted endeavors worldwide, the complexity of the pathophysiology of metabolic syndrome still needs to be clearly understood. Currently, therapeutic possibilities are confined to individual therapy for hyperglycemia, hypertension, hypertriglyceridemia, hyperuricemia, regular physical exercise, and a restricted diet. In this review, progress regarding the understanding and pathophysiology of MetS; recent emerging technologies, such as metabolomics and proteomics; the relation of MetS with obesity, diabetes, and cardiovascular diseases; and the association of MetS with COVID-19 are discussed.

show abstract

Body Mass Index and Risk for COVID-19-Related Hospitalization in Adults Aged 50 and Older in Europe

Cited by 8 publications

References 46 publications

Older Age and Vaccination Protect Against Transaminase Elevation in Pediatric SARS-CoV2

Older Age and Vaccination Protect Against Transaminase Elevation in Pediatric SARS-CoV2

The Impact of COVID-19 Severity on TNF-α and IFN-γ in T2DM Patients' PBMC Monocytes

Progress in Understanding Metabolic Syndrome and Knowledge of Its Complex Pathophysiology

Contact Info

Product

Resources

About